4.6 Article

Bone Disease in CKD: A Focus on Osteoporosis Diagnosis and Management

期刊

AMERICAN JOURNAL OF KIDNEY DISEASES
卷 64, 期 2, 页码 290-304

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.ajkd.2013.12.018

关键词

Chronic kidney disease-mineral and bone disorder (CKD-MBD); osteoporosis; renal failure; bone histomorphometry; parathyroid hormone (PTH); bone-specific alkaline phosphatase

资金

  1. Amgen
  2. Eli Lilly and Co
  3. Merck
  4. Radius Health Inc
  5. Takeda

向作者/读者索取更多资源

Osteoporosis is defined as a condition of impairment in bone strength due to low bone mineral density and poor bone quality and predisposes individuals to an increased risk of fractures. Osteoporosis may coexist with chronic kidney disease-mineral and bone disorder (CKD-MBD) and osteoporotic fractures occur in all stages of CKD. Management of osteoporosis in CKD should consider the pathophysiology of both disorders. Diagnosis and management of osteoporosis in patients with stages 1-3 CKD and patients without CKD are similar, but diagnosis and management decisions differ greatly once patients have stages 4-5 CKD. Discriminating between osteoporosis and CKD-MBD is best accomplished with quantitative bone histomorphometry. Biochemical markers, especially intact parathyroid hormone and bone-specific alkaline phosphatase, also may be helpful. When the diagnosis of osteoporosis is established, management in stages 4-5 CKD may include antiresorptive or anabolic agents, though evidence for efficacy is marginal in advanced CKD. (C) 2014 by the National Kidney Foundation, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据